EBS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Emergent BioSolutions Inc (EBS) is not a strong buy for a beginner, long-term investor at this time. While there are some positive catalysts such as government contracts and improved gross margin, the company's financial performance remains weak with declining revenue and negative net income. Insider selling and bearish technical indicators further suggest caution. Holding off for now is recommended.
The MACD is positive and expanding, indicating potential upward momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key support and resistance levels are at 7.907 and 8.366, respectively.
Emergent BioSolutions secured a $54 million contract with the U.S. Department of Health and Human Services, $6.6 million in new orders for the ACAM2000® smallpox vaccine, and multi-year agreements with the Government of Canada valued at up to CAD 140 million. Gross margin improved by 8.94% YoY.
Revenue dropped by 23.63% YoY in Q4 2025, and the company reported a net loss of $54.6 million. Insider selling has increased by 207.62% over the last month. Analysts have lowered the price target from $15 to $12, citing reduced earnings expectations.
In Q4 2025, revenue declined by 23.63% YoY to $148.7 million. Net income improved but remained negative at -$54.6 million. EPS increased to -1.04, up 79.31% YoY, and gross margin improved to 42.91%.
H.C. Wainwright maintains a Buy rating but lowered the price target from $15 to $12 due to reduced earnings expectations.
